Clinical Operations

Phase I & II Clinical Trials

Phase I & II clinical trials are the first stage of testing a new investigational medicine in humans. The primary focus is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the investigational product and to identify appropriate dose ranges for further clinical development.

Phase I & II studies are typically conducted in a carefully monitored clinical research setting with close observation of participants and systematic collection of safety and clinical data. Depending on the investigational product and study objectives, Phase 1 trials may involve healthy volunteers or patients with the relevant medical condition.

Our approach to Phase I & II research emphasizes participant safety, scientific rigor, regulatory compliance, and high-quality data collection. We work closely with sponsors, investigators, and research teams to ensure that studies are conducted according to approved protocols, Good Clinical Practice (GCP), and applicable regulatory requirements.

Through well-planned and efficiently executed Phase 1 trials, we aim to generate reliable early clinical evidence that supports informed decisions in the subsequent stages of drug development.

Phase III Clinical Trials

Phase III clinical trials are large-scale studies conducted to confirm the efficacy and safety of an investigational medicine in a broader patient population. These trials are a critical stage of clinical development and are designed to generate comprehensive evidence to support regulatory approval and determine the overall benefit-risk profile of the treatment.

Phase 3 studies typically involve a larger and more diverse group of participants and may compare the investigational treatment with a placebo, standard treatment, or another appropriate comparator. Depending on the study design, participants may be followed for an extended period to evaluate treatment effectiveness, safety, and clinically meaningful outcomes.

Our approach to Phase 3 clinical research focuses on patient safety, protocol adherence, data integrity, operational excellence, and regulatory compliance. We collaborate closely with sponsors, investigators, healthcare institutions, and research teams to conduct studies efficiently while maintaining the highest standards of Good Clinical Practice (GCP).

Through well-designed and rigorously conducted Phase 3 trials, we help generate robust clinical evidence that can support regulatory submissions and ultimately contribute to making safe and effective treatments available to patients.

Phase IV Clinical Trials

Phase IV clinical trials are studies conducted after a drug, vaccine, or medical device has received regulatory approval and is available for routine use.

Their main purpose is to monitor long-term safety, effectiveness, and real-world use in a much larger and more diverse population than is usually included in earlier trials.

Post-Marketing Surveillance (PMS) Studies

Post-Marketing Surveillance (PMS) studies are conducted after a medicinal product has received regulatory approval and is available for use in the general population. These studies help evaluate the long-term safety, tolerability, effectiveness, and real-world use of a product under routine clinical practice.

PMS studies play an important role in identifying rare or unexpected adverse events, monitoring the safety profile of a product over time, and understanding its use across diverse patient populations. The information collected can complement data generated during pre-approval clinical trials and support ongoing assessment of the product’s benefit-risk profile.

Our PMS research activities focus on patient safety, data quality, regulatory compliance, and scientifically sound study conduct. We work with sponsors, healthcare professionals, investigators, and other stakeholders to collect and analyze meaningful real-world safety and clinical information.

Expertise in Clinical Trial Execution

Demonstrated expertise in the successful planning, management, execution, and completion of 72 clinical trials across diverse therapeutic areas. This extensive experience encompasses the full clinical trial lifecycle, from study start-up and site selection through patient recruitment, trial conduct, data management, monitoring, regulatory compliance, and study close-out.

Proven ability to effectively manage complex clinical studies while ensuring adherence to ICH-GCP guidelines, applicable regulatory requirements, study protocols, and quality standards. Experienced in coordinating cross-functional teams, investigators, clinical research sites, vendors, and other stakeholders to ensure timely delivery of study milestones and high-quality clinical data.

The experience across multiple therapeutic areas demonstrates strong adaptability and the ability to understand and address disease-specific, patient-specific, operational, and regulatory challenges. This includes effective management of study timelines, risks, resources, documentation, protocol compliance, and quality requirements throughout the clinical development process.

With successful completion of 72 clinical trials, this expertise reflects a strong track record in clinical trial delivery, stakeholder management, operational excellence, quality oversight, and problem-solving, contributing to the reliable and compliant execution of clinical research programs.